王文娴,郑 蕾,宋正波.101例难治性小细胞肺癌的二线治疗生存分析[J].肿瘤学杂志,2015,21(7):546-550.
101例难治性小细胞肺癌的二线治疗生存分析
Analysis of Survival of 101 Cases with Refractory Recurrent Small Cell Lung Cancer with Second-line Treatment
投稿时间:2014-09-27  
DOI:10.11735/j.issn.1671-170X.2015.07.B003
中文关键词:  癌,小细胞  肿瘤复发  二线治疗  生存期  肺肿瘤
英文关键词:carcinoma,small cell  neoplasm recurrence  second-line chemotherapy  survival  lung neoplsms
基金项目:
作者单位
王文娴 浙江中医药大学附属浙江省肿瘤医院浙江省胸部肿瘤(肺、食管)诊治技术研究重点实验室 
郑 蕾 浙江中医药大学附属浙江省肿瘤医院浙江省胸部肿瘤(肺、食管)诊治技术研究重点实验室 
宋正波 浙江中医药大学附属浙江省肿瘤医院浙江省胸部肿瘤(肺、食管)诊治技术研究重点实验室 
摘要点击次数: 2870
全文下载次数: 790
中文摘要:
      摘 要:[目的]探讨含铂双药化疗和单药化疗用于难治复发小细胞肺癌(small cell lung cancer,SCLC)患者二线化疗的疗效及安全性。[方法] 回顾性分析101例难治性SCLC患者二线治疗的疗效和生存情况,并采用Cox多因素分析模型进行预后相关因素的分析。[结果]单药和双药组有效率(response rate,RR) 分别为2.9%和7.5%(P=0.208),疾病控制率 (disease control rate,DCR) 分别为14.7%和59.7%(P<0.001),中位无进展生存期(progression-free survival,PFS)分别为1.23个月和2.77个月(P<0.001)。两组中位总生存期(overall survival,OS)差异无统计学意义(5.40个月vs 5.93个月,P=0.988)。Ⅲ~Ⅳ度不良反应单药组比双药组发生率低(20.6% vs 52.2%,P=0.007)。多因素分析显示体能状况评分(performance status,PS)(HR=1.491,P=0.002)是PFS的独立影响因素。[结论]双药治疗可延长部分患者的PFS,但不良反应相对增加。
英文摘要:
      Abstract:[Purpose] To investigate the efficacy and safety of two-agent chemotherapy (combination chemotherapy) and single-agent chemotherapy(single chemotherapy) based on platinum as second-line chemotherapy in patients with refractory recurrent small cell lung cancer (SCLC).[Methods] The efficacy and survival of 101 cases with refractory recurrent SCLC treated with second-line chemotherapy were analyzed,and prognostic factors were analyzed by COX proportional hazards model.[Results] In single chemotherapy and combination chemotherapy groups,the response rate (RR) were 2.9% and 7.5% respectively(P=0.208);disease control rate,14.7% and 59.7%(P<0.001);median progression-free survival (PFS),1.23 and 2.77 months (P<0.001),with significant difference. And there was no significant difference in median overall survival (OS) in the two groups( 5.40 and 5.93 months,P=0.988).The rate of toxicities grade Ⅲ~Ⅳ in single chemotherapy group was lower than that in combination chemotherapy group (20.6% vs 52.2%,P=0.007).The COX proportional hazards model analysis revealed that performance status score before second-line chemotherapy(0-1 vs 2;hazard ration=1.491,P=0.002) was an independent prognostic predictor of PFS after second-line chemotherapy.[Conclusion] Two-agent chemotherapy as a second-line chemotherapy regimen has an advantage of prolonging PFS,but increases toxicities.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器